Table 2

Clinicopathological features of symptomatic and asymptomatic patients with colorectal cancer

OverallAfter matching
Symptomatic patientsAsymptomatic patientsp ValueSymptomatic patientsAsymptomatic patientsp Value
(n=145)(n=123)(n=80)(n=80)
Age (years)0.950.93
 Median (IQR)67 (60–73)67 (60–75)67 (60–73)67 (59–74)
Sex0.531.00
 Male82 (56.6%)75 (61.0%)40 (50.0%)40 (50.0%)
 Female63 (43.4%)48 (39.0%)40 (50.0%)40 (50.0%)
BMI (kg/m2)0.680.93
 Median (IQR)22.2 (19.7–24.5)22.4 (20.1–24.2)21.9 (19.4–24.4)21.6 (19.0–24.2)
ASA-PS0.0041.00
 1, 2133 (91.7%)122 (99.2%)79 (98.8%)79 (98.8%)
 3, 412 (8.3%)1 (0.8%)1 (1.2%)1 (1.2%)
Prior abdominal operation0.520.63
 Present53 (36.6%)40 (32.5%)33 (41.2%)29 (36.3%)
 Absent92 (63.4%)83 (67.5%)47 (58.8%)51 (63.7%)
PNI0.0050.23
 Median (IQR)49.2 (43.1–52.9)50.7 (46.8–54.7)50.2 (46.0–54.4)51.1 (47.1–55.1)
Serum CEA level (ng/mL)0.0040.66
 Median (IQR)4.0 (2.4–13.0)3.2 (1.9–6.1)3.1 (2.0–6.5)3.6 (2.0–8.2)
Tumour location0.010.87
 Colon79 (54.5%)88 (71.5%)53 (63.3%)51 (63.7%)
 Rectum64 (44.1%)35 (28.5%)27 (33.7%)29 (36.3%)
 Colon and rectum2 (1.4%)0 (0.0%)0 (0%)0 (0%)
Primary tumour<0.0011.00
 Tis, 1, 230 (20.7%)63 (48.8%)27 (33.7%)28 (35.0%)
 T3, 4115 (79.3%)60 (51.2%)53 (63.3%)52 (65.0%)
Lymph node involvement<0.0011.00
 N065 (44.8%)86 (69.9%)44 (55.0%)45 (56.3%)
 N1, 280 (55.2%)37 (30.1%)36 (45.0%)35 (43.7%)
Distant metastasis<0.0010.77
 M0113 (77.9%)116 (94.3%)75 (93.8%)73 (91.3%)
 M132 (22.1%)7 (5.7%)5 (6.2%)7 (8.7%)
Stage<0.0011.00
 Stage 0, I, II62 (42.8%)84 (68.3%)43 (53.8%)43 (53.8%)
 Stage III, IV83 (57.2%)39 (31.7%)37 (46.3%)37 (46.3%)
Residual disease<0.0011.00
 Negative116 (80.0%)118 (95.9%)74 (92.5%)75 (93.8%)
 Positive29 (20.0%)5 (4.1%)6 (7.5%)5 (6.2%)
  • ASA-PS, American Society of Anesthesiologists-physical status; BMI, body mass index; CEA, carcinoembryonic antigen; PNI, prognostic nutritional index.